Drugs / AVX 470
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01759056 Comparator | Feb → Dec 2013 | ulcerative colitis | Avaxia Biologics, Incorporated | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVX-470 | “AVX-470 is an oral, polyclonal bovine-derived anti-tumour necrosis factor (TNF) antibody in development for treatment of inflammatory bowel disease (IBD).” PMID 26822613 ↗ Jan 2016 |
| Action | Inhibit | “AVX-470 neutralizes TNF locally in the gastrointestinal tract, minimizing systemic exposure.” PMID 26822613 ↗ Jan 2016 |
| Modality | Protein / enzyme biologic | “AVX-470 is an oral, polyclonal bovine-derived anti-tumour necrosis factor (TNF) antibody in development for treatment of inflammatory bowel disease (IBD).” PMID 26822613 ↗ Jan 2016 |
| Route | Oral | “multiple doses of AVX-470 administered orally” NCT01759056 ↗ |
| Target | TNF | “AVX-470 neutralizes TNF locally in the gastrointestinal tract, minimizing systemic exposure.” PMID 26822613 ↗ Jan 2016 |